Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06676085

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

ECMO

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age older than 18 years old
  • received ECMO because of severe respiratory failure

Exclusion criteria

  • anticoagulant contraindications
  • cerebral infarction or suspected patients
  • severe hypertension
  • women in gestational and lactational period
  • hemophilia
  • allergic to heparin or Nafamostat
  • unwilling or unable to complete the study

Treatment and study plan

Nafamostat

Drug

Nafamostat combined with unfractionated heparin for anticoagulation

Heparin

Drug

unfractionated heparin for anticoagulation

Primary outcomes

  1. incidence of ECMO related bleeding or thrombotic events

    Time frame: 28 days

    the incidence of ECMO related bleeding or thrombotic events,such as membrane oxygenator or tube thrombotic,local blooding.

Study contacts

Contact information is provided by the study sponsor or research team.

Bing Sun, MD

CONTACT

[email protected]

+8613911151075

Sponsors and collaborators

Lead sponsor

Beijing Chao Yang Hospital

Other

Registry information

Official study title

A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Nov 6, 2024
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.